BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year.
The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug appeared first on MedCity News.
